Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$7.43 -0.20 (-2.62%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$7.34 -0.09 (-1.21%)
As of 05/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Key Stats

Today's Range
$7.15
$7.73
50-Day Range
$5.56
$9.34
52-Week Range
$5.15
$16.81
Volume
1.70 million shs
Average Volume
912,738 shs
Market Capitalization
$646.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33
Consensus Rating
Buy

Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

IMNM MarketRank™: 

Immunome scored higher than 53% of companies evaluated by MarketBeat, and ranked 516th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunome has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Immunome's valuation and earnings.
  • Percentage of Shares Shorted

    16.55% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently increased by 12.13%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.55% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently increased by 12.13%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Immunome has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Immunome this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -96% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,160,495.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

IMNM Stock News Headlines

Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Target Price at $25.33
Trump to redistribute trillions of dollars
Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be laughable if it wasn’t putting so many Americans’ financial futures at severe risk… That’s why, with the 100-day mark of Trump’s second term just days away, it’s time to shine a light on what’s really going on, because if you move your money out of the wrong places and into the right ones before it’s too late… …you could be one of the few who profits from this imminent trillion-dollar reset.
Immunome initiated with a Buy at Lake Street
Clay Siegall Bought 20% More Shares In Immunome
Immunome CEO buys $999.5K in common stock
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $10.62 at the beginning of the year. Since then, IMNM shares have decreased by 30.0% and is now trading at $7.43.
View the best growth stocks for 2025 here
.

Immunome, Inc. (NASDAQ:IMNM) issued its quarterly earnings results on Wednesday, March, 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.16. The firm earned $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative trailing twelve-month return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

Top institutional shareholders of Immunome include TD Asset Management Inc (0.70%), Readystate Asset Management LP (0.26%), Bank of New York Mellon Corp (0.22%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Clay B Siegall, Max Rosett, Bruce Turner, Philip Tsai, Jean Jacques Bienaime, Jack Higgins and Robert Lechleider.
View institutional ownership trends
.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
3/19/2025
Today
5/08/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.33
High Stock Price Target
$33.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+241.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,810,000.00
Net Margins
-3,014.59%
Pretax Margin
-3,014.59%

Debt

Sales & Book Value

Annual Sales
$9.04 million
Price / Cash Flow
N/A
Book Value
$2.77 per share
Price / Book
2.68

Miscellaneous

Free Float
72,916,000
Market Cap
$646.50 million
Optionable
Optionable
Beta
2.00
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners